Last reviewed · How we verify
NCT02970539
Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers
Phase 1 trial testing Oraxol in Gastric Cancer in 36 participants. Status unknown.
27 March 2019
Quick facts
| Lead sponsor | Athenex, Inc. |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 36 |
| Start date | 8 December 2016 |
| Primary completion | 27 March 2019 |
| Estimated completion | 31 December 2022 |
| Sites | 5 locations across Taiwan, United States |
Drugs / interventions tested
- Oraxol — full drug profile →
- Ramucirumab (RAMUCIRUMAB) — full drug profile →
Conditions studied
- Gastric Cancer — all drugs for Gastric Cancer →
- Esophageal Cancer — all drugs for Esophageal Cancer →
- Gastro-esophageal Cancer — all drugs for Gastro-esophageal Cancer →
Sponsor
Athenex, Inc. — full company profile →
Who can join
18 and older, any sex, with Gastric Cancer or Esophageal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a nonrandomized, open-label, single group assignment, safety, tolerability and pharmacokinetic (PK) study to determine the MTD and optimal dosing regimen of Oraxol in combination with ramucirumab.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT02970539
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Oraxol
Trials testing the same drug.
- NCT03892018 — The Effect of Food on the Pharmacokinetics of Paclitaxel Administered Orally as Oraxol · Phase 1 · terminated
- NCT04993040 — A PK Study of Oraxol in Breast Cancer Patients · Phase 1 · completed
- NCT03544567 — A Study of Oraxol in Subjects With Cutaneous Angiosarcoma · Phase 2 · completed
- NCT03588039 — Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors · Phase 1 · terminated
- NCT04168957 — An Extension Study to Provide Oraxol to Patients Who Completed KX-ORAX-007 · Phase 1 · terminated
Other recruiting trials for Gastric Cancer
Currently open trials in the same condition.
- NCT07525765 — AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer · recruiting
- NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
- NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting
Other Athenex, Inc. trials
Trials by the same sponsor.
- NCT04136834 — A Phase I Open-label Study for Subjects With Advanced Malignancies · Phase 1 · unknown
- NCT03892018 — The Effect of Food on the Pharmacokinetics of Paclitaxel Administered Orally as Oraxol · Phase 1 · terminated
- NCT04993040 — A PK Study of Oraxol in Breast Cancer Patients · Phase 1 · completed
- NCT03544567 — A Study of Oraxol in Subjects With Cutaneous Angiosarcoma · Phase 2 · completed
- NCT03588039 — Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors · Phase 1 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02970539 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Athenex, Inc.
- Last refreshed: 16 February 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02970539.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing